Search bioRxiv⌕ Search

Biology subjects

Carlotti, F.

Publications and source records attributed to Carlotti, F..

3 recordsLinked to original sources

Compromised beta-cell identity in type 2 diabetes

Compromised beta-cell identity is emerging as an important contributor of beta-cell dysfunction in type 2 diabetes (T2D). Several studies suggest that hyperglycemia induces the inactivation of transcription factors involved in mature beta-cell identity. More specifically, chronic hyperglycemia leads to the downregulation of PDX1 and MAFA, two important beta-cell identity transcription factors and regulators of insulin promoter activity. Regulation of these transcription factors depends on interactions between multiple signaling cascades and processes driven by complex non-linear dynamics and taking place in different cellular compartments. To better understand these non-linear dynamics, we developed an integrated mathematical model of the underlying mechanisms regulating these key transcription factors. Our model was able to reproduce experimentally measured variations in the levels of PDX1, MAFA and insulin mRNA under different glucose concentrations. We used this model to simulate scenarios that could allow to restore PDX1 and MAFA levels and therefore insulin gene expression. From these simulations, FOXO1 emerged as an important target for the restoration of beta-cell identity. Author summaryGlucose regulation depends on the secretion of insulin by beta-cells and uptake of glucose by the peripheral cells mediated by the action of insulin. In type 2 diabetes both aspects can be compromised. Defective insulin secretion results from compromised beta-cell function. One of the reasons behind compromised beta-cell function is that beta-cells fail to express one or more of the genes involved in insulin production and secretion and thus maintenance of beta-cell identity. The processes involved in the regulation of insulin production and secretion are complex. In this work, we are particularly interested in the role and downregulation of transcription factors, PDX1 and MAFA, which are critical regulators of insulin production, in relation with compromised beta-cell identity and function in the presence of chronic hyperglycemia. To understand better these complex processes, we use mathematical modelling which enables to generate hypotheses and simulate scenarios to extend our understanding of the mechanisms leading to compromised beta-cell function in the presence of chronic hyperglycemia. Our model and similar models can serve to identify therapeutical targets in beta-cells in order to restore their function.

systems biology↗

PCSK9 affects expression of key surface proteins in human pancreatic beta cells through intra- and extracellular regulatory circuits

Aims/hypothesisProprotein convertase subtilisin/kexin 9 (PCSK9) is involved in the degradation of LDLR. However, PCSK9 can target other proteins in a cell-type specific manner. While PCSK9 has been detected in pancreatic islets, its expression in insulin-producing pancreatic beta cells is debated. Herein, we studied PCSK9 expression, regulation and function in the human pancreatic beta cell line EndoC-{beta}H1. MethodsWe assessed PCSK9 expression in mouse and human pancreatic islets, and in the pancreatic beta cell line EndoC-{beta}H1. We also studied PCSK9 regulation by cholesterol, lipoproteins, Mevastatin, and by SREBPs transcription factors. To evaluate PCSK9 function in pancreatic beta cells, we performed PCSK9 gain-and loss-of-function experiments in EndoC-{beta}H1 using siPCSK9 or recombinant PCSK9 treatments, respectively. ResultsWe demonstrate that PCSK9 is expressed and secreted by pancreatic beta cells. In EndoC-{beta}H1 cells, PCSK9 expression is regulated by cholesterol and by SREBPs transcription factors. Importantly, PCSK9 knockdown results in multiple transcriptome, proteome and secretome deregulations and impaired insulin secretion. By gain- and loss-of-function experiments, we observed that PCSK9 regulates the expression levels of LDLR and VLDLR through an extracellular mechanism while CD36, PD-L1 and HLA-ABC are regulated through an intracellular mechanism. Conclusions/interpretationCollectively, these results highlight PCSK9 as an important regulator of CD36, PD-L1 and HLA-ABC cell surface expression in pancreatic beta cells. Data availabilityRNA-seq data have been deposited to GEO database with accession number GSE182016. Mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the following identifiers: PXD027921, PXD027911 and PXD027913.

cell biology↗

Organization and dynamics of the cortical complexes controlling insulin secretion in β-cells.

Insulin secretion in pancreatic {beta}-cells is regulated by cortical complexes that are enriched at the sites of adhesion to extracellular matrix facing the vasculature. Many components of these complexes, including Bassoon, RIM, ELKS and liprins, are shared with neuronal synapses. Here, we show that insulin secretion sites also contain non-neuronal proteins LL5{beta} and KANK1, which in migrating cells organize exocytotic machinery in the vicinity of integrin-based adhesions. Depletion of LL5{beta} or focal adhesion disassembly triggered by myosin II inhibition perturbed the clustering of secretory complexes and attenuated the first wave of insulin release. While previous analyses in vitro and in neurons suggested that secretory machinery might assemble through liquid-liquid phase separation, analysis of endogenously labeled ELKS in pancreatic islets indicated that its dynamics is inconsistent with such a scenario. Instead, fluorescence recovery after photobleaching and single molecule imaging showed that ELKS turnover is driven by binding and unbinding to low-mobility scaffolds. Both the scaffold movements and ELKS exchange were stimulated by glucose treatment. Our findings help to explain how integrin-based adhesions control spatial organization of glucose-stimulated insulin release.

cell biology↗